Cardiol Therapeutics raises $7M via warrant exercises ahead of Phase III readout
What's the deal? Cardiol TherapeuticsDealroom has a profile for this one. Try Dealroom → has raised more than $7 million through the exercise of outstanding common share purchase warrants. The Canada-listed company (TSE:CRDL) says the capital extends its cash runway into the first half of 2028.
Why now? The raise lands ahead of a pivotal Phase III MAVERIC trial data readout in recurrent pericarditis, an inflammatory heart condition. Management says the warrant exercises "signal shareholder confidence" as Cardiol nears the milestone.
What's the endgame? Cardiol is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx, holds US Food and Drug Administration Orphan Drug Designation for pericarditis; the company is also advancing CRD-38, a subcutaneous formulation for inflammatory heart disease.
Where the money goes: Funds are earmarked to support regulatory preparations and broader pipeline development. Cardiol has also triggered an acceleration right on remaining warrants, setting an early expiry in October 2026, after which any unexercised warrants will be cancelled — potentially adding further proceeds if exercised.
What could go wrong? As a pre-revenue biotech, Cardiol carries large ongoing losses and material cash burn. The Phase III readout is binary: strong data could be transformative, while a miss would leave the company reliant on its extended runway with no near-term revenue.
The signal: For a small-cap biotech with a US$237.3M market cap, warrant exercises offer a low-friction way to shore up the balance sheet before a make-or-break trial. It buys time and flexibility without a dilutive new raise — leverage that only holds if the data cooperates.
Read more: tipranks.com
